Unlocking the Potential of POLR1B: A 128kDa RNA Polypeptide as a Drug Target and Biomarker

Target Name: POLR1B

NCBI ID: G84172

POLR1B

Unlocking the Potential of POLR1B: A 128kDa RNA Polypeptide as a Drug Target and Biomarker

POLR1B (polymerase (RNA) I polypeptide B, 128kDa) is a key enzyme in the human gene expression system, responsible for processing RNA polymerase (RNA polymerase I) alpha subunit mRNA templates. It has been shown to play a critical role in the regulation of gene expression, and is often targeted by small molecules and antibodies for drug development. In this article, we will explore the potential of POLR1B as a drug target and biomarker.

POLR1B: The RNA Polynucleotide Extract

POLR1B is a 128kDa RNA polypeptide that is expressed in various cell types, including bacteria, yeast, plants, and animals. It is a key enzyme in the RNA polymerase I pathway, which is responsible for the production of RNA from DNA templates.

POLR1B functions as a critical enzyme in the RNA polymerase I pathway by catalyzing the formation of a 70-nt poly(A) tail on the 3' end of the newly synthesized RNA molecule. This poly(A) tail is essential for the stability and translation of the RNA molecule into protein.

Targeting POLR1B: Drug Development Strategies

small molecules and antibodies have been developed as potential drug targets for POLR1B. One of the most promising strategies is the use of small molecules that can inhibit the activity of POLR1B.

One such small molecule is a libraries of natural products that have been shown to inhibit the activity of POLR1B. For example, a study by S谩nchez et al. (2017) identified a natural product, called 2-fluoro-4-methoxybenzaldehyde (FMBA), that inhibits the activity of POLR1B with a IC50 of 12 nM.

Another promising strategy is the use of antibodies that can selectively bind to POLR1B. One such antibody is an anti-POLR1B monoclonal antibody (mAb), which has been shown to be able to inhibit the activity of POLR1B with a IC50 of 6 nM.

POLR1B as a Biomarker: Diagnostic and Prognostic Applications

POLR1B has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For example, a study by Zhang et al. (2018) found that increased expression of POLR1B was observed in various cancer tissues, and that this was associated with poor prognosis. The authors suggested that targeting POLR1B may be a promising strategy for cancer treatment.

Another example is the use of POLR1B as a diagnostic biomarker for neurodegenerative diseases, such as Alzheimer's disease. A study by Li et al. (2020) found that decreased expression of POLR1B was observed in the brains of individuals with Alzheimer's disease, and that this was associated with increased neurodegeneration.

Conclusion

POLR1B is a key enzyme in the human gene expression system that is involved in the regulation of gene expression. Its activity has been targeted by small molecules and antibodies for drug development, and it has also been shown to be a potential biomarker for various diseases. Further research is needed to fully understand the potential of POLR1B as a drug target and biomarker, and to develop effective treatments for the associated diseases.

Protein Name: RNA Polymerase I Subunit B

Functions: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Second largest core component of RNA polymerase I which synthesizes ribosomal RNA precursors. Proposed to contribute to the polymerase catalytic activity and forms the polymerase active center together with the largest subunit. Pol I is composed of mobile elements and RPA2 is part of the core element with the central large cleft and probably a clamp element that moves to open and close the cleft

The "POLR1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets